User:Mr. Ibrahem/Respiratory syncytial virus vaccine

Respiratory syncytial virus vaccine (RSV vaccine), sold under the brand name Abrysvo and Abrysvo, is a vaccine which protects against respiratory syncytial virus. It is used in those who are 24 to 36 weeks pregnant to protect the baby and in those over the age of 60. It is given as a single dose by injection into muscle of the arm. It decreases the risk of severe disease by about 50 to 85%.

Common side effects include pain at the site of injection, tiredness, headache, and muscle pain. These typically resolve in a couple of days. Effects on the risk of preterm birth is unclear as of 2023. It works by teaching the immune system how to defend the body against RSV. Arexvy contains a version of the protein RSVPreF3 while Abrysvo contains subgroup A and B stabilised prefusion F.

The vaccines were approved for medical use in the United States, Europe, and Canada in 2023. In British Columbia, Canada it costs about 230 CAD and is available for private purchase as of 2023. Research for these vaccines has been ongoing since the 1950s and 60s; with a study published in 2013 leading to current vaccines. The underlying science supported the rapid development of COVID-19 vaccines.